Teva’s Fremanezumab (Ajovy) Reported as Cost Effective for Migraine

Migraine TrialsiteN

Ajovy is a drug for migraine prevention. It has been shown to be effective and safe in adult patients suffering from four or more attacks per month. Discovered and developed by Rinat Neuroscience, it came to Pfizer via acquisition in 2006 and thereafter was licensed to Teva.  It was approved by the FDA in September, 2018. By April, 2019 it was approved by the European Union. It is still being evaluated for diseases other than migraine.  Teva is still developing it for episodic cluster headache but stopped development of the drug for the treatment of chronic headache in 2018 after the primary endpoint of a Phase III trial was not met.

The Institute for Clinical Economic Review (ICER) released a final evidence report evaluating effectiveness and value of GCRP inhibitors last year, finding that fremanezumab was lower than the $150,000 per quality-adjusted life year (QALY) threshold in prevention of chronic migraine and were nearly equivalent to the threshold in episodic migraine.

Follow the link below to source at AJMC for further reading on this topic.